Stevanato Group(STVN) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - For fiscal 2025, total company revenue increased by 9% at constant currency rates and 7% on a reported basis compared to 2024, reaching EUR 1.26 billion to EUR 1.29 billion for 2026 guidance [5][23] - Gross profit margin rose by 160 basis points compared to 2024, driven by strong performance in High-Value Solutions [6] - For the fourth quarter of 2025, total company revenue grew 7% at constant currency and 5% on a reported basis to EUR 346.5 million [16] Business Line Data and Key Metrics Changes - The Biopharmaceutical and Diagnostic Solutions (BDS) segment delivered double-digit growth, with revenue increasing 13% at constant currency and 10% on a reported basis for Q4 2025 [16][19] - Revenue from High-Value Solutions grew 31% to EUR 171 million in Q4 2025, representing approximately 49% of total company revenue for the quarter [17] - The engineering segment experienced a 23% revenue decline in Q4 2025, attributed to lower revenue in glass conversion and assembly [20] Market Data and Key Metrics Changes - Revenue from GLP-1s accounted for approximately 19%-20% of total company revenue in 2025, growing more than 50% compared to 2024 [8] - The company expects GLP-1s to serve as a meaningful tailwind as patient demand continues to grow, with a projected mid-teens growth rate for 2026 [29][30] - Biologics represented 41% of BDS revenues in 2025, up from 34% in 2024, indicating a growing market presence [10] Company Strategy and Development Direction - The company is focused on high-value solutions and has invested in expanding capacity for high-value syringes in Fishers, Indiana, and Latina, Italy [7] - The strategy includes pivoting away from non-high-value product categories and increasing participation in the broader set of biologic applications [10][15] - The company aims to align growth investments with customer demand trends and capitalize on opportunities in the evolving market [15][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the robust demand for biologics and the company's ability to meet this demand through its integrated value proposition and innovative products [25] - The company anticipates that the engineering segment will take longer to regain momentum due to a slower-than-expected sales cycle [32] - Management highlighted the importance of operational progress and the expectation of benefiting from new capacity and productivity gains in the future [26][25] Other Important Information - The company ended fiscal 2025 with cash and cash equivalents of EUR 130.6 million and net debt of EUR 337.7 million, indicating a solid liquidity position [21] - Capital expenditures for 2025 totaled EUR 294.9 million, with approximately 89% allocated for growth projects [21] Q&A Session Summary Question: Expectations for GLP-1 growth in 2026 - Management expects GLP-1 revenue growth in the mid-teens for 2026, following a 50% growth in 2025 [29] Question: Insights on engineering segment order intake - Management noted that the sales cycle for engineering projects is longer than anticipated, but the order pipeline remains healthy [31] Question: Capacity constraints for High-Value Solutions - Management confirmed that capacity constraints were experienced in 2025, but robust demand is expected to continue into 2026 [37] Question: Long-term growth outlook for GLP-1s - Management believes GLP-1s will continue to be a significant growth driver, with a strong demand forecast for the next decade [46][80] Question: Performance of non-GLP biologics - Management indicated that non-GLP biologics are expected to grow, with a focus on high-value products and increasing customer engagement [68]